Jonathan Barratt
Overview
Explore the profile of Jonathan Barratt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
208
Citations
5706
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheung C, Barratt J
Semin Nephrol
. 2025 Mar;
:151573.
PMID: 40057426
The past few years have heralded a sea change in the treatment landscape of IgA nephropathy (IgAN). An increasing understanding of its pathogenesis coupled with favorable changes in the regulatory...
2.
Kavanagh D, Barratt J, Schubart A, Webb N, Meier M, Fakhouri F
Front Immunol
. 2025 Mar;
16:1537974.
PMID: 40028332
The complement system, consisting of three initiating pathways-classical, lectin and alternative, is an important part of innate immunity. Dysregulation of the complement system is implicated in the pathogenesis of several...
3.
Floege J, Bernier-Jean A, Barratt J, Rovin B
Kidney Int
. 2025 Feb;
PMID: 39894081
IgA nephropathy (IgAN), the world's most common primary glomerular disease, carries a significant lifetime risk for kidney failure as well as an enormous socioeconomic burden. In the past, studies in...
4.
5.
Heerspink H, Jardine M, Kohan D, Lafayette R, Levin A, Liew A, et al.
Kidney Int Rep
. 2025 Jan;
10(1):217-226.
PMID: 39810771
Introduction: Endothelin A (ETA) receptor activation is a driver of proteinuria, kidney inflammation, and fibrosis in IgA nephropathy (IgAN). Atrasentan, a selective ETA receptor antagonist, has potential to reduce proteinuria...
6.
Zhang H, Lafayette R, Wang B, Ying L, Zhu Z, Stone A, et al.
Kidney360
. 2024 Dec;
5(12):1881-1892.
PMID: 39724565
Background: IgA nephropathy (IgAN), an immune-mediated kidney disease, is particularly prevalent among individuals of East Asian ancestry. Nefecon is a novel, oral, targeted-release budesonide formulation designed to inhibit galactose-deficient IgA1...
7.
Angell B, Wang S, Gadsden T, Moorthy M, Malik C, Barratt J, et al.
Kidney Int Rep
. 2024 Dec;
9(12):3553-3569.
PMID: 39698356
Introduction: Rare kidney diseases (RKDs) place a substantial economic burden on patients and health systems, the extent of which is unknown and may be systematically underestimated by health economic techniques....
8.
Unwin R, Challis B, MacPhee I, Hansen P, Jones R, Salama A, et al.
Nephrol Dial Transplant
. 2024 Nov;
PMID: 39611334
No abstract available.
9.
Kanbay M, Ozbek L, Guldan M, Copur S, Barratt J
J Nephrol
. 2024 Nov;
PMID: 39565563
IgA nephropathy is the commonest pattern of primary glomerular disease in the world, with high rates of progression to kidney failure. As IgA nephropathy commonly causes kidney failure at a...
10.
Barratt J, Barbour S, Brenner R, Cooper K, Wei X, Eren N, et al.
J Am Soc Nephrol
. 2024 Oct;
PMID: 39462308
No abstract available.